Your browser doesn't support javascript.
loading
Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib.
Sunga, Cass G G; Higgins, Michael S; Ricciotti, Robert W; Liu, Yajuan J; Cranmer, Lee D.
Afiliación
  • Sunga CGG; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • Higgins MS; PeaceHealth Department of General and Colorectal Surgery, Bellingham, Washington, USA.
  • Ricciotti RW; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Liu YJ; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Cranmer LD; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Cancer Rep (Hoboken) ; 6(3): e1792, 2023 03.
Article en En | MEDLINE | ID: mdl-36754839
BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is an ultra-rare soft tissue neoplasm associated with fusion proteins encompassing the anaplastic lymphoma kinase (ALK) protein fused to a variety of partner proteins. Data regarding response to ALK-targeting agents based on fusion partner is limited. CASE: A 30-year-old female sought emergency care after onset of abdominal and lower back pain in 2019. Computed tomography (CT) demonstrated a cystic, mesenteric mass within the pelvis measuring up to 8.9 cm. Complete laparoscopic excision of the mass from the mesentery of the right colon and terminal ileum was performed. Pathologic assessment revealed IMT with a fusion between sequestosome 1 and ALK (SQSTM1::ALK), described in only two other cases of IMT. Four months after surgery, CT revealed multi-focal, unresectable disease recurrence. She was referred to the University of Washington/Fred Hutchinson Cancer Center and placed on therapy with alectinib, after which she experienced a partial response. Three years after IMT recurrence, disease remains under control. CONCLUSION: This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. Treatment with the ALK inhibitor alectinib appears to be active in this setting.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidinas / Recurrencia Local de Neoplasia Límite: Adult / Female / Humans Idioma: En Revista: Cancer Rep (Hoboken) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidinas / Recurrencia Local de Neoplasia Límite: Adult / Female / Humans Idioma: En Revista: Cancer Rep (Hoboken) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos